Author: admin

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

POLIOMYELITIS VACCINE, LIVE (ORAL) I.P. (DI-VALENT)
(Bivalent/b-OPV) Type 1 & Type 3

Oral Polio is a serious but preventable disease. In India, hundreds and thousands of infants and children used to get infected with polio virus and suffer from its serious consequences mainly paralysis.

DESCRIPTION :

Bio-Med’s Oral Polio Vaccine is prepared using attenuated Sabin Strain Polio viruses. The vaccine is clear light pink in liquid form and light pale yellow in frozen form. Bio-Med’s Oral Polio Vaccine conforms to Indian Pharmacopoeia

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3892″ img_size=”medium” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

Each dose of vaccine contains :

Particulars	Quantity
Attenuated Sabin strain virus Type 1	10⁶ CCID₅₀
Attenuated Sabin strain virus Type 3	10^5.8 CCID₅₀
MgCl₂(Stabilizer)	1M
Kanamycin Sulphate (Preservative)	20mcg per dose

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block4″][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″ el_class=”img”][vc_column_text]IMMUNIZATION SCHEME :

Poliomyelitis vaccine is indicated for prevention of Poliomyeltis against Type 1 & 3 polio Viruses, pulse polio program and in supplementary immunization activities(SIA’s) in children from 0-5 years of age. The doses and interval of Poliomyelitis vaccination should be according to National Policy.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block5″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]PRESENTATION :

Squeezable Plastic tube with VVM Label (20 dose). This is latest generation packing is superior in handling quality, leak proof and nozzle designed to deliver exact drops of vaccine.
In glass vial with VVM Label (20 dose) and sterile plastic dropper.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432458076{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block6″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″][vc_column_text]VVM ( Vaccine Vial Monitor) Label :

Bio-Med in an effort to improve product quality came up with the state of the art labeling of Oral Polio Vaccine with imported VACCINE VIAL TIME TEMPERATURE SENSITIVE INDICATOR for the first time in India.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block7″][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]BENEFITS OF USING VVM (Vaccine Vial Monitor) :

Ensures efficacy with round the clock surveillance from the manufacturer to final user.
Improved confidence in the quality and reliability of the product.
Demonstrates compliance with handling rules / regulations.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″][vc_column_text]CONTRA- INDICATION :

Immunodeficiency- Individuals infected with human immunodeficiency virus (HIV) both asymptomatic and symptomatic should be immunized with the vaccine according to standard schedule. However the vaccine is contraindicated for those with primary immuno deficiency disease or suppressed immune response from medication such as leukemia, lymphoma or generalised malignancy.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432608841{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block9″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″][vc_column_text]DOSAGE AND ADMINISTRATION :

2 drops (0.1 ml) of the vaccine is administered orally.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block10″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″][vc_column_text]STORAGE :

Vaccine is potent if stored at or below -20ºC until the expiry date indicated on the label

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]PPD – Polio Divalent

SmPC Polio (Divalent)

POLIOMYELITIS[/vc_column_text][/vc_column][/vc_row]

Human Products

Rabies Vaccine, Human I.P. Sure Rab™

Post author By admin
Post date December 5, 2017
No Comments on Rabies Vaccine, Human I.P. Sure Rab™

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]DESCRIPTION :

It is an inactivated, purified and lyophilized preparation of Pitman Moore strain of rabies virus. The virus is produced on VERO cell culture and inactivated by ?-propiolactone. Sure Rab superscript is manufactured as per Indian Pharmacopoeia. The manufacturing facilities meets the requirement as per cGMP guidelines of revised schedule ‘M’ of the Drugs & Cosmetics Act, Government of India

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3954″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

Each single dose lyophilized vaccine contains : Inactivated, Rabies virus………………………?2.5IU
Stabilizer: Polygeline, Sucrose, Salts

• Hyper sensitivity to any of the vaccine component.
• Acute infection or febrile illness.

• No case of harm attributable to use of Rabies Vaccine during pregnancy have been observed to-date in mothers or children.
• It is not known whether Rabies Vaccine passes into breast milk. No risk to the breast- feeding infant has been described to-date.
•It is advisable to carefully weigh expected benefits against potential risks prior to pre- exposure immunization during pregnancy and breast-feeding.

The vaccine should be shaken gently and visually inspected for any foreign particulate matter and/or variation of physical aspect prior to administration. In the event of either of the above being observed, discard the vaccine. As with other vaccines, in rare cases anaphylactic shock may occur in susceptible individual. The mainstay in the treatment of severe anaphylaxis is the prompt use of adrenaline, which can be life saving. It should be used at the first suspicion of anaphylaxis. The vaccines should remain under observation for not less than 30 minutes for possibility of occurrence of rapid allergic reactions. Hydrocortisone & antihistamines should also be available in addition to supportive measures such as oxygen inhalation.

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″][vc_column_text]Storage :

Store between 2^oC to 8^oC in the refrigerator. The shelf life of Product is 36 months from the date of manufacture if stored in recommended storage condition.

The corticosteroids and immunosuppressive treatment may lead to vaccination failure.

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]PRESENTATION

Single dose vial with appropriate diluent ,disposable syringe and needle

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]SIDE EFFECT :

Ask for any active product, there may be more or less moderate and temporary side effects like :

Pain, induration, erythema, pruritis at the injection site.
Rare, transient, febrile reactions.
Rarely anaphylactic reactions, urticaria, rash may be encountered.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]SURE RAB

PPD- Sure Rab

SmPC-SURE RAB[/vc_column_text][/vc_column][/vc_row]

Human Products

Peda Hib™

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

(Haemophilus type b conjugate vaccine)

Peda Hib™ is a highly purified vaccine prepared from capsular polysaccharide (polyribitol phosphate) short named PRP, covalently bonded to tetanus toxoid protein. Addition of lactose and freeze-drying has resulted in a highly stable vaccine.
This vaccine induces ‘T’- cell dependent immune response in infants that is essential for appropriate initial humoral antibody response and priming for booster effects (anamnestic response) of subsequent vaccinations. Such immune response is lacking in vaccines prepared from unconjugated PRP. Peda Hib™ has been manufactured using the latest technology to remove contaminants eg. L.P.S. pyrogens to make it the least reactogenic but highly immunogenic vaccine. Thus Peda Hib™ is the latest generation vaccine of the best quality in its class.
Peda Hib™ conforms to I.P.

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3895″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

Each Single dose of lyophilisate contains :

Particulars	Quantity
Purified Polysaccharide of Haemophilus influenzae type b (PRP)	10 mcg
Tetanus Toxoid protein	20 mcg
Lactose (I.P.) (Stabilizer)	2 mg
Sucrose (I.P.) (Stabilizer)	42.5 mg
Thimerosal (I.P.) ( Preservative)	0.05 mg

Peda Hib™ is indicated for the prevention in children from 6 weeks to 5 years age, of invasive diseases caused by Haemophilus influenzae type b e.g. Meningitis, cellulitis, epiglottitis. In no case can the tetanus protein contained in Peda Hib™ replace the routine tetanus vaccination.

One dose in glass vial with appropriate diluent.

Reconstitute the lyophilisate with the entire content of the diluent provided. Shake gently for full reconstitution. Administer 0.5 ml by intramuscular injection.

(A) Before 6 moths : Peda Hib™ can be administered to infants from the age 1.5 month with three injection of one dose(0.5ml) at intervals or one or two months followed by a booster (4th injection) at 15-18 months

(B) Between 6 to 12 Months : Two injections at interval of one or two months followed by a booster (3rd injection) at 15-18 month

(C) Between 1 to 5 years : One single injection[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block7″][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]CONTRA- INDICATION :

• Acute infection or febrile illness.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]POSSIBLE SIDE EFFECT :

As in the case of any active product, there may be more or less moderate and temporary side effects. Mild local pain, redness, induration or fever may occur during the 48 hrs following injection.
D.P.T. vaccine causes more or less moderate temporary side effects, similar side effects may be observed when Peda Hib Superscript is administered after reconstituting with D.P.T. vaccine.

The vaccine must be stored at 2° C -8°C . Shelf life of Peda Hib Superscript is 3 years from the date of manufacture.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block10″][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Peda Hib IP

PPD – PEDA HIB I.P

PPD – PEDA HIB as per WHO TRS

SmPC Peda Hib as per WHO TRS

SmPC Peda Hib IP[/vc_column_text][/vc_column][/vc_row]

Human Products

Quadri Meningo™

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

(Meningococcal Polysaccharide Vaccine)
(Group A, C, Y & W135)

Meningitis or Meningococcemia is caused by Neisseria meningitidis (Groups A, C, Y, W135) bacteria. It may be severe and life threatening. A variety of neurological and immunological complications are generally associated with the primary disease.

DESCRIPTION :

QUADRI MENINGO superscript is to be used to protect against cerebrospinal meningitis caused by Neisseria meningitidis (Group A, C, Y & W 135). Quadri Meningo superscript conforms to the I.P.

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3890″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

Each dose (0.5 ml) of vaccine contains :

Particulars	Quantity
Purified Polysaccharide of Neisseria meningitidis Group A	50 mcg
Purified Polysaccharide of Neisseria meningitidis Group C	50 mcg
Purified Polysaccharide of Neisseria meningitidis Group Y	50 mcg
Purified Polysaccharide of Neisseria meningitidis Group W 135	50 mcg
Lactose I.P. (Stabilizer)	5 mg
Thimerosal I.P. (Preservative)	0.05 mg

Hajj and Umrah pilgrims heading to Mecca, Saudi Arabia.
Children and adults exposed to infected patients.
Recommended for children above 18 months of age as routine immunization in endemic areas.
Travellers heading to disease prone areas should be vaccinated at least 15 days in advance.
Military recruits.
During epidemic, children between 3-18 months need to be vaccinated 3 months apart. Revaccination is recommended in children at high risk areas who were vaccinated below 4 years of age.

QUADRI MENINGO TM is available in single dose vial with syringe and 10 dose vial packing along with appropriate diluent

Reconstitute The lyophilisate with the entire content of the provided with vaccine vaccine Inject 0.5 ml as S/C or I/M injection.

• Hypersensitivity to any of the vaccine component.
• Ongoing acute or chronic illness like fever, severe infection, persistent diarrhoea, vomiting.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]SIDE EFFECTS :

Reaction to vaccination generally consists of localized injection site reaction ( Pain , redness) , Transient hyperthermia , headache,vomiting in children etc.

Store at 2° C to 8° C in refrigerator. Product is good to use for 24 months from the date of manufacture.

W.H.O has recommended use of Quadrivalent Vaccine (containing A, C, Y & W 135) in place of bivalent vaccine (containing only A, C ) specially in areas like India where group specific meningococci – causing the disease have not been identified.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Quadri Meningo as per WHO TRS

Quadri Meningo IP

PPD – QUADRI MENINGO as per WHO TRS

PPD – QUADRI MENINGO I.P

SmPC Quadri meningo as per WHO TRS

SmPC Quadri meningo IP

[/vc_column_text][/vc_column][/vc_row]

Human Products

Bio Typh™

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

Typhoid Polysaccharide Vaccine-
“Big concern, small solutions”

Typhoid fever is a contagious and severe disease due to a bacterium called Salmonella typhi. It mostly affects school-age children. Typhoid fever is a widespread disease that is easily transmitted.
It is present in all tropical regions, including our country where it affects most of the population. Each year, over 33 million people worldwide catch Typhoid fever and about 200,000 die.
Bio-Med successfully developed typhoid polysaccharide vaccine and launched it in November 1998. This is the first indigenously manufactured Vi antigen typhoid vaccine and is manufactured as per Indian Pharmacopoeia.

DESCRIPTION :

Bio Typh™ is a clear solution containing purified Vi capsular polysaccharide of Salmonella typhi for prevention of typhoid fever. It contains 25 mcg of Vi antigen per dose and is in liquid form.

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3898″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

Each dose (0.5 ml) of vaccine contains :

Particulars	Quantity
Vi polysaccharide of Salmonella typhi	25 mcg
Phenol I.P. (Preservative)	max. 0.25%
Isotonic saline q.s.	0.5 ml

• Children aged 2 years or more and adults.
• Travellers proceeding to endemic areas.
• Mela / fair visitors.
• Vendors of unprotected food.
• Settlers in poor hygienic areas.

Single dose vial (0.5ml)
Prefilled syringe (0.5ml)
5 dose vial
10 dose vial

• Inject 0.5 ml in adults and children over 2 years of age by intramuscular or subcutaneous route.
• Vaccine provides protection for a period of three years.
• Reimmunization every three years under conditions of repeated or continued exposure is recommended.
• Prevention becomes effective 2-3 weeks after immunization.

• Hypersensitivity to any constituent of the vaccine.
• Pregnant and lactating women.
• In the event of fever or severe infection,diarrhoea, dysentery,debilitating ailment,abdominal pain etc

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]SIDE EFFECTS :

Mild local pain, redness, induration and mild fever may occur during the 48 hours following injection in few cases.

Store between 2⁰C – 8⁰C. Do not freeze. Product is good for use within 30 months from the date of manufacture.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block9″][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Bio Typh IP

PPD – BIO TYPH I.P.

PPD – BIO TYPH as per WHO TRS

SmPC Bio Typh as per WHO TRS

SmPC Bio Typh -IP[/vc_column_text][/vc_column][/vc_row]

Human Products

Boto Genie superscript

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

BOTULINUM TOXIN TYPE A

(PURIFIED NEUROTOXIN COMPLEX)

DESCRIPTION :

BOTO GENIE superscript is a biologically active and highly purified preparation of Botulinum toxin Type A. This is an extremely potent neurotoxin complex which causes relaxation of muscles, marked reduction in gland secretory activity and silencing of nociceptor function on its absorption. The medical science has developed methodology to derive magical drug effect by unique formulation and controlled administration techniques. It has been used to correct undesirable muscular activity for a considerable period without surgical intervention. This action is reversible in nature in a few months. Since BOTO GENIE superscript is in a highly purified form & is used in minute quantities, it does not induce any immunological response even after several treatments in most subjects. BOTO GENIE superscript conforms to Ph.Eur.

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3888″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION :

BOTO GENIE superscript 100 or 50 unit vial (Freeze dried )
Botulinum toxin Type A………….100 / 50 units
(Purified Neurotoxin Complex )
Lactose (Stabilizer ) ……………..5mg
Reconstitute with diluent provided
(Sodium chloride injection I.P., 0.9% W/V)

Available in 50 &100 unit vial along with appropriate.

Safe and effective use of BOTO GENIE superscript depends on selection of correct dose and administration techniques. It is extremely important for physician to know the detailed muscular & other anatomical aspect of the area proposed to be treated, any alteration to the anatomy due to prior surgical procedure for good results and success.

• Hypersensitivity to any ingredient in formulation.
• Infection at the proposed site of inoculation.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]SIDE EFFECTS :

Localized weakness of the injection muscle (S) represents the expected desirable action of the drug , however weakness of adjacent muscles may also occur due to spread of toxin

Skin rash , pruritus , allergic reaction , localized pain , bruising may be associated with the injection which may occur rarely
Overdose : Excessive doses may cause distant and profound neuromuscular paralysis. There is no specification antidote. General supportive care is advised

Store BOTO GENIE^® at 2⁰C to 8⁰C.
Shelf life of BOTO GENIE^® is 36 months.
BOTO GENIE^® reconstituted in aseptic conditions can be stored at 2⁰C to 8⁰C for 4 hrs.

SmPC-BOTOGENIE[/vc_column_text][/vc_column][/vc_row]

Human Products

Bi Meningo™

[vc_row css=”.vc_custom_1512431460697{margin-bottom: 0px !important;}”][vc_column width=”2/3″ el_class=”block1″][vc_column_text]

MENINGOCOCCAL POLYSACCHARIDE VACCINE
(Group A & C)

DESCRIPTION :

Meningococcal Polysaccharide vaccine is to be used to protect against cerebrospinal meningitis and other diseases caused by Neisseria meningitidis (Group A & C). Bi Meningo™ fulfills the requirements of Meningococcal Polysaccharide Vaccine as given in Indian Pharmacopoeia.The manufacturing facilities meets the requirements of cGMP guidelines of revised schedule ‘M’ of Drugs & Cosmetics Act of Government of India

[/vc_column_text][/vc_column][vc_column width=”1/3″ el_class=”block2″][vc_single_image image=”3886″ img_size=”full” alignment=”center” el_class=”img”][/vc_column][/vc_row][vc_row el_class=”product-box” css=”.vc_custom_1512432424869{padding-top: 35px !important;}”][vc_column width=”1/3″ el_class=”block3″][vc_row_inner css=”.vc_custom_1512431727138{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3346″ img_size=”24×24″ el_class=”img”][vc_column_text]INDICATIONS

Vaccination is recommended in regions of endemic infection, travelers to countries with epidemic meningococcal disease, household or institutional contacts, military recruits etc.

It is also recommended for subjects living in closed communities and close contacts of patients/carriers of Meningococcal Group A & C.[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block4″][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″ el_class=”img”][vc_column_text]COMPOSITION

Each dose (0.5ml) of vaccine contains:
Purified Polysaccharide of Neisseria meningitidis
-Group A…………………………….50 µg.
-Group C…….………………………50 µg.
-Lactose I.P.( Stabilizer)…………….5 mg.
-Thiomerosal I.P.(Preservative)…0.05 mg.

Administer the vaccine(0.5 ml) by intramuscular or subcutaneous route.

Hypersensitivity to any of the vaccine component.
Ongoing acute or chronic illness like fever, severe infection, persistent diarrhoea, vomiting

Administration of single 0.5ml dose of Bi Meningo™ (Group A & C) elicits a significant bactericidal antibody response in about 100% of subjects. Immunity is conferred for three years.
The seroconversion rate of children vaccinated under the age of two years is lower for the serogroup C. However, the seroconversion rate for the sero-group A is acceptable in children from the age of 6 months onwards.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block8″][vc_row_inner css=”.vc_custom_1512429922882{margin-top: 0px !important;margin-bottom: 0px !important;}”][vc_column_inner][vc_single_image image=”3352″ img_size=”24×24″][vc_column_text]SIDE EFFECTS

Reaction to vaccination generally consists of localized injection site reaction (pain, redness), transient hyperthermia, headache, vomiting in children etc.

Store between 2^oC to 8^oC in the refrigerator. Product is good to use for 24 months from the date of manufacture.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″ el_class=”block9″][vc_row_inner el_class=”product-border”][vc_column_inner][vc_single_image image=”3353″ img_size=”24×24″][vc_column_text]PRESENTATION

1. One dose in glass vial with diluent and disposable syringe.
2. Ten dose in glass vial with diluent.

[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/3″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]Bi meningo as per WHO TRS

Bi meningo IP

PPD – BI MENINGO as per WHO TRS

PPD – BI MENINGO IP

SmPC Bi meningo as per WHO TRS

SmPC Bi meningo IP

[/vc_column_text][/vc_column][/vc_row]